Intuitive Surgical, Inc. (NASDAQ:ISRG) SVP Sells $272,651.64 in Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) SVP Mark Brosius sold 492 shares of the company’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $554.17, for a total value of $272,651.64. Following the sale, the senior vice president now owns 3,072 shares of the company’s stock, valued at approximately $1,702,410.24. This trade represents a 13.80 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Mark Brosius also recently made the following trade(s):

• On Monday, March 3rd, Mark Brosius sold 492 shares of Intuitive Surgical stock. The shares were sold at an average price of $573.78, for a total value of $282,299.76.

Intuitive Surgical Trading Down 5.2 %

Shares of Intuitive Surgical stock opened at $538.57 on Friday. The stock has a 50 day moving average of $571.70 and a 200 day moving average of $530.95. Intuitive Surgical, Inc. has a 12 month low of $364.17 and a 12 month high of $616.00. The firm has a market cap of $191.83 billion, a PE ratio of 84.02, a PEG ratio of 5.85 and a beta of 1.43.

Analyst Ratings Changes

A number of research firms recently commented on ISRG. BTIG Research upped their price objective on Intuitive Surgical from $535.00 to $561.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Stifel Nicolaus upped their price objective on Intuitive Surgical from $525.00 to $610.00 and gave the company a “buy” rating in a research report on Thursday, December 5th. Truist Financial upped their price target on Intuitive Surgical from $640.00 to $666.00 and gave the stock a “buy” rating in a research report on Friday, January 24th. Raymond James upped their price target on Intuitive Surgical from $560.00 to $688.00 and gave the stock an “outperform” rating in a research report on Friday, January 24th. Finally, Bernstein Bank upped their price target on Intuitive Surgical from $655.00 to $700.00 and gave the stock an “overweight” rating in a research report on Monday, January 27th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $613.10.

Hedge Funds Weigh In On Intuitive Surgical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Norges Bank bought a new stake in shares of Intuitive Surgical in the 4th quarter valued at approximately $2,401,493,000. Massachusetts Financial Services Co. MA bought a new stake in shares of Intuitive Surgical in the 3rd quarter valued at approximately $558,807,000. Proficio Capital Partners LLC lifted its stake in shares of Intuitive Surgical by 89,098.8% in the 4th quarter. Proficio Capital Partners LLC now owns 949,967 shares of the medical equipment provider’s stock valued at $495,845,000 after purchasing an additional 948,902 shares during the last quarter. FMR LLC lifted its stake in shares of Intuitive Surgical by 8.3% in the 3rd quarter. FMR LLC now owns 10,971,085 shares of the medical equipment provider’s stock valued at $5,389,765,000 after purchasing an additional 838,793 shares during the last quarter. Finally, Capital Research Global Investors lifted its stake in shares of Intuitive Surgical by 25.5% in the 4th quarter. Capital Research Global Investors now owns 3,381,302 shares of the medical equipment provider’s stock valued at $1,764,904,000 after purchasing an additional 687,906 shares during the last quarter. 83.64% of the stock is owned by institutional investors.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.